Combining Cancer Immunotherapies
Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.
- Targeted therapies
- Rationale for immunotherapy
- Combining radiotherapy
- Standard therapies
- Androgen manipulation
- T-cell modulation
- Inter-Leukeins
- Interferons
- T- cell growth
- Cell Proliferation
Related Conference of Combining Cancer Immunotherapies
5th International conference on Vaccines, Vaccination and Immunization
Combining Cancer Immunotherapies Conference Speakers
Recommended Sessions
- Antibody Therapy of Cancer
- Brain Tumors
- Cancer & HIV
- Cancer biomarkers
- Cancer clinical trials
- Cancer Genomics and Metabolomics
- Cancer Immunology & Immunotherapy
- Cancer micro and immuno environment
- Cancer Pharmacology
- Cancer Prognosis & Diagnosis
- Cancer Research & Cancer vaccines
- Combining Cancer Immunotherapies
- Immune checkpoint inhibitors
- Immuno-Oncology studies
- Novel Approaches in Cancer & Tumor
- Radiology and Imaging in Cancer
- Stem Cell Therapy
- Tumor biology
- Tumor Immunology
- Tumor immunotherapy research
- Tumor markers and drug targeting
- Tumors
- Types of cancer
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)